The Hindu·3 min read·medium
Leqembi for early Alzheimer's treatment launched in India after CDSCO nod
P
PTI
✦AI Summary
Japanese pharmaceutical company Eisai has launched Leqembi in India following approval from the CDSCO for the treatment of early-stage Alzheimer's disease. This therapy is the first disease-modifying treatment available in the country for patients with mild cognitive impairment and mild dementia.
Japanese pharmaceutical company Eisai on Monday announced the launch of Leqembi (lecanemab) in India for the treatment of early Alzheimer's disease after procuring marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO).
healthbusinessscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in